摘要
Abstract
Objective To explore the cost-effectiveness analysis of ipratropium bromide combined with budesonide and terbutaline in the treatment of asthmatic bronchitis in children. Methods A total of 87 patients with moderate asthmatic bronchus admitted to Dandong Women and Children's Hospital from June 2016 to December 2017 were selected as study objects, and were randomly divided into observation group (44 cases) and control group (43 cases). On the basis of conventional treatment, the control group was additionally treated with budesonide combined with terbutamine inhalation, and the observation group was treated with ipratropium bromide combined with budesonide and terbutamine inhalation. Clinical efficacy, time of clinical symptom hospitalization, occurrence of adverse reactions, cost-effectiveness analysis and sensitivity analysis were compared between the 2 groups. Results The total therapeutic efficiency rate of the observation group was 90.91％, which was higher than 72.09％ of the control group (P<0.05). The hospitalization time and clinical symptom disappearance time of the observation group were significantly shorter than that of the control group (all P<0.05), and the cost-effectiveness ratio of the observation group was significantly lower that of the control group. Cost-effectiveness analysis showed that the observation group had more advantages. Conclusion Ipratropium bromide combined with budesonide and terbutaline atomization inhalation in the treatment of asthmatic bronchitis can significantly shorten the course of treatment, improve the cure rate, reduce the burden of patients and reduce the waste of medical resources such as drugs, which has good economic significance.关键词
喘息性支气管炎/异丙托溴铵/特布他林/布地奈德/成本-效果分析Key words
Asthmatic bronchitis in children/Ipratropium bromide/Budesonide/Terbutaline/Cost-effectiveness analysis分类
医药卫生
